GTC Biotherapeutics (fka GTCB)

[ThomasS]

An honest, but simple observation from a naive biotech investor, noting that boredom may factor in to some of the postings here of late:

1. Does anyone realistically expect the HD trial to fail?
2. Does anyone realistically expect less than a substantial partnership deal, given the huge potential market for ATRYN AD/HD? (This will be the big event near-term, imo, not the trial results.)

If the answer to the above is universally "no," then why fret and lose hope at a multi-year low pps? Be realistic.
I'd be purchasing more if not already engorged beyond acceptable principles; simply put, this is not a case where pps accurately belies the underlying prospects.
Again, the partnership deal will, in sum, exceed the current market cap by multiples, imo. Someone will then take notice :)